Life Sciences Archive » April, 2014

Life Sciences - April, 2014

354 articles

• Endo To Pay $830M To Settle Most Vaginal Mesh Cases
• Pfizer unit, Mutual To Pay $73M To Settle Pay-For-Delay Claims
• US Spurns Eli Lilly's Bid To Prod Canada On Drug Patents
• House Dem To Target DOJ Nonprosecution Deals In New Bill
• Despite Dip In Pharma M&A, Oncology Remains Hot
• Democrats Seek GAO Inquiry On Women In Clinical Trials
• Ivera IV Disinfectant Cap Patents Invalid, Judge Finds
• 3rd Circ. Shuts Down Generic Fosamax Appeal
• Deals Rumor Mill: Etihad, Oprah, Pfizer
• GMO-Labeling War Wages On, Now With Congress Weighing In
• China Puts Conditions On $2.6B Merck-AZ Deal
• FDA Rips Glucose Strip Maker, Issues Safety Alert
• 3rd Circ. Won't Nix Pa. Doctor's Fen-Phen Fraud Convictions
• FDA Must Change Labeling On Heartburn Meds: Watchdog
• Female Powerbrokers Q&A: Hausfeld's Megan Jones
• Female Powerbrokers Q&A: Gunster's Lila Jaber
• Endo Birth Control Suits Belong In Georgia, Plaintiffs Say
• India Court Puts $3.2B Sun Pharma, Ranbaxy Merger On Hold
• Debate Over Categorizing Qualified Health Plans Continues
• Preemption Redemption
• Produce Documents 'Subject To' Objections At Your Own Risk
• Medtronic Is Owed $33M In Spine Device Deal, Jury Told
• Celgene Attacks Whistleblower's FCA Off-Label Suit
• SAC Fights Elan, Wyeth Investor Suit Over Insider Trading
• High Court Nailed It With Actavis, FTC's Ohlhausen Says
• $100B Pfizer Tie-Up Plan Puts Focus On US Corporate Exodus
• Appeals Court Affirms RSUI Win In Forest Lab Coverage Spat
• Deals Rumor Mill: Alstom, Allergan, Bayer
• Akin Gump Snags Former FDA Lawyer For Health Practice
• Warner Chilcott's Chewable Birth Control Patent Is Obvious
• The Golden State Warrior: Judge S. James Otero
• Actavis Standard Transcends Cash Deals, FTC Tells 3rd Circ.
• Female Powerbrokers Q&A: Kirkland's Anne McClain Sidrys
• Female Powerbrokers Q&A: Porter Hedges' Joyce Soliman
• FDA Moves To Require Premarket Approval For Vaginal Mesh
• Kirkland & Ellis Reps Bristol Myers In $175M IPierian Buy
• Fla. Senate OKs Limited Legalization Of Medical Marijuana
• Justices Blast Fed. Circ. Patent Indefiniteness Test
• NJ Pharma Wholesaler Says Drugmaker Won't Share Profits
• Mintz Levin Snags Ex-Morrison & Foerster IP Expert
• Deals Rumor Mill: Alstom, Premier Oil, American Realty
• 5 Years After FERA, FCA Landscape Still Unsettled
• Pozen Says FDA Blocked Drug Products Over Quality Lapses
• Illumina Hits Ariosa With IP Suit Over Prenatal Test
• Md. High Court Says Off-Label Status Doesn't Show Drug Risks
• NJ Appeals Court Backs Arbitration In Merck Licensing Row
• AbbVie, Abbott, Others Want Testosterone Injury Cases In Ill.
• 5 Fights Over $25B Actavis-Forest Deal Merge In NY
• Watson, Mylan Slam FDA Over Generic Celebrex Decision
• New Exclusivity For Fixed-Dose Drugs Will Help Small Cos.
• FDA Bans Labels Claiming High Levels Of Omega-3
• Skadden Helps Pfizer With Potential $100B AstraZeneca Bid
• Female Powerbrokers Q&A: Patton Boggs' Laura Weidenfeld
• Female Powerbrokers Q&A: Axelrod Firm's Sheryl Axelrod
• Forest Labs Puts Up $1.5B For Furiex Pharmaceuticals
• Meda Again Shrugs Off $24B Mylan Merger Plan
• It's An Honor To Be Your Friend?: Social Media And Judges
• GCs Name Most Elite Law Firms
• 5 Pharma Ad Enforcement Trends To Watch
• Amarin Targets Apotex, Roxane Over Vascepa Generics
• AbbVie Hits Hetero USA With 2nd Suit Over Norvir Generic
• Legal And Ethical Risks Drug Companies Face In China
• Avandia User's Consumer Fraud Suit Dies In 3rd Circ.
• Deals Rumor Mill: Alstom, Dell, Allergan
• Prestige Brands To Drop $750M For Insight Pharmaceuticals
• Crowell Nabs Nixon Peabody Partner For DC Corporate Group
• FDA Won't Label Tooth Whiteners As Drugs
• Female Powerbrokers Q&A: Nicolaides' Sara Thorpe
• Female Powerbrokers Q&A: Strasburger's Kim Moore
• Takeda Won't Commit To Cover Eli Lilly For $9B Verdict
• Ark. Supreme Court Won't Rehear $1.2B Risperdal Case
• Fed. Circ. Stays Out Of USPTO Decisions To Open AIA Reviews
• Actavis Reaches Deal With Pfizer To Sell Generic Celebrex
• Life Sciences, Tech IPOs Soared In 2013
• Ex-Patent Holder Can't Appeal USPTO Ruling, Fed. Circ. Says
• Spanish Consumers Ask Watchdog To Probe Roche, Novartis
• Hyperion To Pay Up To $600M For Israeli Diabetes Drug Co.
• Female Powerbrokers Q&A: Williams & Connolly's Enu Mainigi
• Female Powerbrokers Q&A: Dorsey's Liz Buckingham
• Biomet Opts For $13.4B Sale To Zimmer, Halts IPO Plans
• USPTO Guidance Brings US In Line With Global Policy
• Legal Evolution: Back To Business
• Stryker Can't Dodge Howmedica Worker Reimbursement Suit
• Myriad Asks Fed. Circ. To Block Ambry Cancer Test In IP Row
• FDA Warns Of Fatal Risks In Widely Used Epidurals
• FDA Gets Heat On Pharma Ad Risk Disclosures
• Janssen Claims Preemption In $4M Topamax Defect Appeal
• Major Changes Come To China's Medical Device Industry
• NJ Court Skins Attys For Divulging Merck Deal Months Later
• FDA Advisory Panel Votes Down New Opioid Painkiller
• USPTO's Verdict-Nixing Power Must Be Reined In, Baxter Says
• 4 Practice Areas Generating Big Billable Hours
• Generic Cos. Seek To Appeal Androgel Dismissal Denial
• FDA Rips Providers For Shoddy Clinical Trial Oversight
• Supplement Maker Xymogen Faces Toxic Warning Label Suit
• Female Powerbrokers Q&A: Curtis' Nancy Delaney
• Female Powerbrokers Q&A: Alston Hunt's Anna Elento-Sneed
• High Health Ad Standards May Hurt Consumers: FTC Commish
• Allergan Swallows Poison Pill After $46B Valeant-Ackman Bid
• CVS Decries Novartis Kickback Suit As 'Implausible'
• Ropes & Gray SF Head Jumps To Gibson Dunn
• Hydroxycut Users Settle For Less In $14M False Ad MDL Deal
• The Accidental Advocate: Judge John E. Jones III
• Ex-Celgene Exec Gets 16 Months For Insider Trading Plot
• Mandatory Pro Bono Is Not The Answer For Practitioners
• Fed. Circ. Revives Tamiflu Case, Expands Double-Patenting
• GSK Slams Mylan's Bid For $3.1M Interest In Paxil Row
• Fed. Circ. Flips Braintree Win In Generic Suprep Suit
• Proskauer Lures Bingham Life Sciences Patent Litigator
• Low-THC Marijuana Legalization Moves Ahead In Fla. Senate
• Perrigo Wants Hurry-Up On Delayed FDA Drug Rating
• Pharma M&A Boom Means Big Payday For Wide Swath Of Firms
• Bayer Says IRS Has Burden Of Proof In $175M R&D Tax Row
• Rising Star: Kirkland & Ellis' Mike Shumsky
• Daiichi Blasts Conditional Cert. Bid In $100M Sex Bias Case
• Female Powerbrokers Q&A: Priest Johnson's Priest Johnson
• Female Powerbrokers Q&A: BakerHostetler's Lauren Resnick
• IMS Health Launches New Coverage Suit Over Antitrust Claims
• FDA Details Fast-Track Approach For Medical Devices
• Mallinckrodt, Nuvo Sue Metrics Over Generic Pennsaid
• Courts Split On Applying Therasense To Summary Judgment
• Novartis Unveils $30B In Deals To Drive Strategic Overhaul
• Generic Cos. Again Lose Bid To Shake AndroGel Suit
• Endo Hit With TCPA Junk Fax Suit Over Unsolicited Drug Ads
• Ex-Genta Exec Settles SEC Insider Suit Over Melanoma Drug
• Valeant, Ackman Put $42B Botox Maker On Takeover Hit List
• No Sanctions For Takeda Doc Destruction In Ill. Cancer Trial
• Fla. Medical Marijuana Bill Clears House Committee
• Pharma Cos. Press FDA For Track-And-Trace Flexibility
• Deals Rumor Mill: AstraZeneca, Barrick Gold, Charter
• Fed. Circ. Upholds Abbott's $16M Win Over Tarka Patent
• Rising Star: Jones Day's Colleen Heisey
• Fed. Circ. Stays Medtronic Valve Injunction In Patent Row
• Only 7 BigLaw Firms Have Women Running The Show
• Merck Delays $2.6B Buy To Win Over Chinese Antitrust Agency
• J&J, Ethicon Fight Against Pa. Pelvic Mesh Remand
• Pfizer Strikes $190M Deal To Settle Neurontin Antitrust MDL
• J&J Can't Shake Former Worker's Severance Pay Suit
• Judge OKs $64M Baxter Plasma Products Antitrust Deal
• Pronova Wants High Court's Slant On 'Public Use' Patent Bar
• Philly Mass Tort Filings Saw Steep Dip In 2013, Report Finds
• Female Powerbrokers Q&A: Allen Matkins' Amy Wintersheimer
• Female Powerbrokers Q&A: Horvitz & Levy's Lisa Perrochet
• Bayer Kills 'Misrepresentative' Mark For 'Flanax' At TTAB
• An Accused Infringer's Guide To Parallel Proceedings
• Skadden, Cleary Help Seal Sweetened $461M Chindex MBO
• Cross-Border Complexities: Keep The C-Suite Out Of Prison
• The 25 Best Law Firms For Female Partners
• Impax Can't Shake Drug Quality-Control Securities Action
• Whistleblower Wants High Court's Stance On Leave To Amend
• Nordic Naturals Defeats Stink Over Fish Oil Fraud
• Weight Loss Supplement Co. Sued Over Missing Cactus
• McKenna Long Tried To 'Destroy' Heart Tronics, Suit Says
• USC Urges Judge To Toss Ex-Football Player's Pain Med Suit
• Edwards Says Valve Ban Should Stand, Citing Scare Tactics
• $9.5B Of Venture Capital Injected In Q1, PwC Says
• Chief Justice Denies Teva's Bid To Block Generic MS Drugs
• Mylan Hit With IP Suit Over Generic Cholesterol Drug
• FDA Expands Review Of Pharma Promo Risk Perception
• Rising Star: Alston & Bird's Sarah Ernst
• 3rd Circ. Urged To Move GSK Paxil Suit Back To State Court
• FTC Wants Closer Look At $25B Actavis-Forest Labs Deal
• Female Powerbrokers Q&A: Nicolaides' Monica Sullivan
• Female Powerbrokers Q&A: Sutherland's Cynthia Shoss
• The Future Of Law Firm PR: The Good, Bad And Ugly
• FDA Approves Stronger Warning Labels For Opioids
• Perkins Coie Reels In Product Liability Pro From DLA Piper
• King & Spalding Nabs Life Sciences Pro From DLA Piper
• Eli Lilly, Others Hit Apotex With IP Suit Over Heart Drug
• Teva Offers To Post $500M Bond For Stay On Copaxone Order
• ACA Sign-Ups Hit 8M In Win For Health Care Industry
• FDA Warns Of Cancer Risks With Fibroid Removal Procedure
• Pfizer, Kaiser End Neurontin Off-Label Suit With Fee Deal
• Endo, Noven Ink Settlement Over Lidoderm Patch Patent
• American Capital Inks $291M Sale Of Pharma Co. SPL
• Executors Of BMS CEO's Estate Can't Shake $6M Tax Suit
• Teva Strikes Deal With Pfizer To Sell Generic Celebrex
• Female Powerbrokers Q&A: Jenner's Barbara Steiner
• Female Powerbrokers Q&A: Dorsey's Annette Jarvis
• FTC Continues To Target Pharmaceutical Mergers
• 8th Circ. Won't Rehear Eli Lilly Failure-To-Warn Suit En Banc
• China's Challenge To Vitamin C Price-Fixing Ruling On Point
• Ex-Stryker, Sanofi Execs Sentenced For Insider Trading
• USPTO Takes Second Shot At Patent Eligibility Guidance
• A Blow To State Encroachment On Federal Turf
• Glenmark Sues Sanofi To Clear Way For Antidiuretic
• Endo Hit With FDA Warning Over Vaginal Mesh Facility
• Cygnus Shakes Attys' Fees In Endoscopy Kit Patent Suit
• Deals Rumor Mill: Ahli, Michael Foods, SodaStream
• Astellas To Pay $7M To End Mycamine FCA Suit
• J&J Unit Bombs 6 Attempts To Ditch Humira Patent Suit
• GSK Investigating Employee Bribery In Jordan, Lebanon
• Sandoz Can't Pare Claim From Generic Remodulin Suit
• Big Pharma Tears Into FDA's Social Media Guidance
• Female Powerbrokers Q&A: Williams & Connolly's Hubbard
• Female Powerbrokers Q&A: Holland & Knight's Laurie Daniel
• Stolen Roche Cancer Drug Tampered With, Reintroduced In EU
• Medtronic Judge Backs Up Ban As Case Heads To Fed. Circ.
• Daiichi Can't Delay Class Cert. Ruling In $100M Sex Bias Suit
• The Great Persuader: 7th Circ. Chief Judge Diane Wood
• Mass. Court Upends Gov.'s Zohydro Ban
• Sen. Floats Bill to Combat Antibiotic-Resistant Microbes
• Deals Rumor Mill: ConMed, GEA Group, Telefonica
• Medicines Co. Sues Aurobindo Over Angiomax Generic
• Are You Covered For Food Product Recalls?
• Actavis, Mylan Settle IP Suit Over Generic Birth Control Drug
• Fed. Circ. Boots Injunction On Boston Scientific Catheter
• EU Parliament Approves €22B Innovation Investment Package
• Great American Seeks To Limit Meningitis Outbreak Coverage
• Female Powerbrokers Q&A: Veenker Law's Vicki Veenker
• Female Powerbrokers Q&A: BakerHostetler's Pennington
• You Should Fear The Regulator, GCs Say
• Litigation Stays Steady But Firms' Costs Keep Rising
• Heartbleed Rains On The Legal Cloud Parade
• Consequential Damages Clause At Heart Of $100M Dispute
• USTR Urged To Pressure Canada On Revoked Drug Patents
• Millennium Gets Claims Cut From Ameritox False Ad Suit
• FTC Orders Akorn To Sell Drug Lines For $640M Merger
• Herbalife Investor Files Class Action After Gov't Probes
• Bayer Escapes Bulk Of Trasylol Off-Label Marketing Suit
• Mintz Levin Nabs 3 Patent Pros For Boston Office
• DOJ Intervenes In Power Wheelchair False Claims Suit
• Medtronic Asks Fed. Circ. To Lift CoreValve Sales Ban
• Depomed Settles With Incepta, Zydus Over Nerve Pain Drug
• FDA Seeks To Stay Perrigo Suit Over Delayed Rating Update
• Philips Dodges 3rd Defibrillator Patent Row
• Deals Rumor Mill: Novartis, Disney, Shell
• J&J Surgical Mesh Recipient Wins Remand Of Injury Suit
• Myriad Loses Fed. Circ. Bid For Quick Cancer Test Appeal
• Female Powerbrokers Q&A: Rimon's Robin Powers
• Female Powerbrokers Q&A: Allen Matkins' Sandi Nichols
• Roche's Boniva Patents Are Obvious, Fed. Circ. Affirms
• Varian Settles With Pitt For $35M After Fed. Circ. Ruling
• DOJ, FBI Investigating Herbalife After FTC Civil Inquiry
• Justices Asked To Leave USPTO Verdict-Nixing Power Intact
• FDA Chief Wants Global Effort To Keep Drugs, Food Safe
• NH Sen. Urges FDA To Monitor Abuse Risks Of Zohydro
• Celgene Gets Claims Trimmed From Andrulis Drug Patent Suit
• Utah US Atty To Step Down, Rejoin Sidley Austin
• EU Agency To Inspect Testosterone Drugs In Medicine Review
• Female Powerbrokers Q&A: Jeffer's Louise Ann Fernandez
• Female Powerbrokers Q&A: Susman Godfrey's Brooke Taylor
• SPCs — We Wait In Vain For Clarity From Europe
• Keep Your Audience From Checking Email: 5 Legal Talk Tips
• Rising Stars: 2014's Top Attorneys Under 40
• The 2014 Rising Stars, By Firm
• Pharma Co. Hit With Investor Suit Over Sponsored Blog Posts
• Class Cert. Granted In Cold Medicine Marketing Row
• Nev. Judge Shuns 'Outrageous' Recusal Bid In Actos Suit
• Smith & Nephew Pays $12M To Settle ArthroCare Merger Suits
• Fed. Circ. Tells Court To Rethink Pitt's $110M Patent Award
• Nicaragua Ducks $12M Pharma Sale Suit In 11th Circ.
• Pelvic Mesh Plaintiffs Want Suits Back In Pa. State Court
• Wal-Mart Escapes Suit Over Misleading Migraine Meds
• Roche, Novartis Face French Antitrust Probe Over Eye Drugs
• Female Powerbrokers Q&A: Jenner's Susan Kohlmann
• Female Powerbrokers Q&A: Strasburger's Betsy Kamin
• DaVita Ducks Manufacturing Claims Over Dialysis Products
• Warner Chilcott Sues Over Erectile Dysfunction Drug License
• Novartis Wins Jury Verdict In Jaw-Injury Suit
• AMAG Pharma Fails To Shirk Drug-Risks Investor Suit
• 2014 Signals The Return Of The Megamerger
• Banks Sue Olympus Over $1.7B Accounting Scandal
• Workers Fund Says Takeda, Generics Delayed Diabetes Drug
• New EU Tech Regulations Will Impact Life Sciences
• 2 Inside Traders Of Celgene, Stryker Stock Get Prison Time
• St. Jude Targets Amgen Over DNA, Cancer Research Patents
• Deals Rumor Mill: Seibu, Ranbaxy, Huarong
• Female Powerbrokers Q&A: Paradigm's Maureen Dorney
• Female Powerbrokers Q&A: O'Brien And Ryan's Hansen
• Doc Destruction Likely Fired Up Jury Behind $6B Actos Verdict
• Teva Changed Its Tune on OxyContin Patent, Purdue Claims
• Branch Law Firm Says Avandia Fee Claim Must Be Arbitrated
• Del. Court Issues Warrant In WL Gore Trade Secrets Case
• Fed. Circ. Asked To Uphold Boston Scientific Injunction
• Justice Of The Peace: CIT Chief Judge Donald Pogue
• High Court Prods Generics Makers On Teva's Copaxone Bid
• Drug Design Defect Claims Post-Bartlett
• Husch Blackwell Snags Ex-Thompson Coburn Health IP Pro
• Big Pharma Consolidation Underpins Deal Making In 2014
• 2nd Circ. Asked To Reverse $153M Vitamin C Antitrust Award
• OIG Report Backs CMS In Competitive Bidding Row
• FDA Ignored Device Reclassification Process, DC Circ. Told
• Zohydro Maker Sues Mass. Gov. To Stop Drug's Ban
• Female Powerbrokers Q&A: Sheppard Mullin's Whitney Roy
• Female Powerbrokers Q&A: Saul Ewing's Debbie Spranger
• JPML Won't Join Diet Pill Suits Against USPlabs, GNC
• $9B Verdict Hammers Takeda, Eli Lilly In Actos Bellwether
• Teva Asks Supreme Court To Block Generic MS Drugs
• FTC Looks To Ax Cephalon Patent Experts In Antitrust Case
• High Court Poised To Set New Bar For Class Action Removal
• O'Melveny Nabs Patent Atty Trio For NY Office
• Eli Lilly Urges High Court To Affirm Inducement Rule
• 3rd Circ. Told GSK Violated Avandia Warranty
• Medtronic Escapes 1st Bone-Graft Device Injury Trial
• Roche Inks Potentially $450M Deal For Diagnostic Device Co.
• Sanofi Escapes Antitrust Suit Over Lovenox Contracts
• BioMed Realty Enters New Haven With $308M Office Investment
• Merck Accuses Expert Of Leaking Confidential Vioxx Docs
• Celesio Investors Hold Back Support For $5.5B McKesson Bid
• High Court Mulls Class Action Removal In Oil Royalty Row
• Female Powerbrokers Q&A: Bilzin Sumberg's Amaducci
• Female Powerbrokers Q&A: Steinman & Rodgers' Rodgers
• Latham, Wachtell Steer $5.6B Mallinckrodt-Questcor Merger
• Pros And Cons Of Trial Presentation Software Programs
• Shearman Guides Sun Pharma To $3.2B Ranbaxy Merger
• Sanofi Hid MS Drug's Checkered History, Investors Say
• Jury Says NuVasive Owes $30M In Neurovision Trademark Row
• SEC Threats Don't Help In-House Bar Prevent Retaliation
• 9th Circ. Allows Expert Testimony In Novartis Jaw Injury Row
• Mylan Claims Celgene Is Blocking Cancer Drug Generics
• J&J Inks Settlements In 76 Topamax Birth Defect Suits
• J&J Hit With $1.2M Verdict In Texas Pelvic Mesh Trial
• Direct Purchasers Denied Cert. In Transitions Antitrust Row
• Female Powerbrokers Q&A: Pillsbury's Elizabeth Moeller
• Female Powerbrokers Q&A: Feinberg Day's Elizabeth Day
• Swedish Drugmaker Meda Spurns $24B Mylan Merger Pitch
• How Omnicare Vs. Laborers Reached The High Court
• JPML Combines Boehringer Pay-For-Delay Suits In Conn.
• FDA Stays Hands-Off In Long-Awaited Health IT Report
• ITC Says Digital File Transfers Are Imports Under Tariff Act
• Apple, Ford, Pfizer, Others Team Up To Protect US Patents
• FDA Clears Overdose Antidote Amid Zohydro Uproar
• Cardinal Health Drops $320M On Medical Device Co.
• Int'l Approach Floated For Medical App Regulation
• Jenner & Block Buoys Pharm Practice With Ropes Patent Ace
• Female Powerbrokers Q&A: Caldwell's Robyn Crowther
• Female Powerbrokers Q&A: Wendel Rosen's Patricia Curtin
• FDA Bans Imports From Apotex's India Drug Plant
• 'Doc Fix' Shakes Up Wide Range Of Health Policies
• FDA To Recognize Same-Sex Couples In Regulations
• McDermott Will & Emery Launches Health Care Lobbying Arm
• IMS Health Sees Insurers Try To Jump Antitrust Coverage
• AstraZeneca Can't Shake Palmetto's Crestor Patent Fight
• J&J Unit Can't Escape TCPA Junk Fax Suit
• CORRECTED: 6 Ex-Mintz Levin Attys To Expand Cooley Life Sciences IP Team
• Female Powerbrokers Q&A: Farella Braun's Stephanie Skaff
• Female Powerbrokers Q&A: Haynes And Boone's Jan Sharry
• Pamplona Capital Buys Majority Stake In Generic-Drug Maker
• Similarities In Ark. And La. Medicaid False Claims Cases
• Burns & Levinson Snaps Up 5 Attys For Expanding IP Practice
• Weakened Patent Rights Make Trade Secrets More Attractive
• The Lion In Winter: Judge Stephen Reinhardt
• FDA Finalizes Board Member Conflict Of Interest Policies
• NuVasive Exec Defends 'Neurovision' Trademark
• GOP Reps. Want Minutes Of FDA Meeting With Trial Lawyers
• FDA Pushes For Greater Clinical Trial Patient Diversity
• Schiff Hardin Nabs Ex-Winston & Strawn IP Expert
• I-Flow Reaches Infusion Pump Patent Settlement With Rival
• Commercial Speech Issues Remain After FDA Guidance
• Steris Puts Up $175M For Medical Instrument Co.
• Female Powerbrokers Q&A: Saul Ewing's Jennifer Peterson
• Female Powerbrokers Q&A: Sheppard Mullin's Betsy McDaniel
• GSK Plans Recall After FDA Warning Over Tainted Batches